Theravance Biopharma SVP Áine Miller to depart Nov 15, 2026 as part of restructuring

Theravance Biopharma, Inc.

Dr. Miller, SVP Development and Head of Ireland Office, will terminate on Nov 15, 2026.
Termination is part of the restructuring announced by the Company in March 2026.
Company will make a special pension contribution of $250,000 within 30 days of termination.
Dr. Miller received a grant of 18,750 RSUs for continued service through the Termination Date.
Compromise agreement and side letter entered into on June 19, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.